Table of Contents Author Guidelines Submit a Manuscript
Journal of Pharmaceutics
Volume 2014, Article ID 265754, 14 pages
http://dx.doi.org/10.1155/2014/265754
Review Article

Combinative Particle Size Reduction Technologies for the Production of Drug Nanocrystals

1Institute of Pharmacy, Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Freie Universität Berlin, Kelchstraße 31, 12169 Berlin, Germany
2Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Knollstraße, 67061 Ludwigshafen am Rhein, Germany

Received 31 January 2013; Accepted 7 May 2013; Published 6 January 2014

Academic Editor: Waquar Ahsan

Copyright © 2014 Jaime Salazar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. van Eerdenbrugh, G. van den Mooter, and P. Augustijns, “Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products,” International Journal of Pharmaceutics, vol. 364, no. 1, pp. 64–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Möschwitzer and R. H. Müller, “New method for the effective production of ultrafine drug nanocrystals,” Journal of Nanoscience and Nanotechnology, vol. 6, no. 9-10, pp. 3145–3153, 2006. View at Google Scholar
  3. J. Salazar, J. Möschwitzer, and R. H. Müller, “Performance comparison of two novel combinative particle size reduction technologies,” Journal of Pharmaceutical Sciences, vol. 102, no. 5, pp. 1636–1649, 2013. View at Publisher · View at Google Scholar
  4. S. Verma, R. Gokhale, and D. J. Burgess, “A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions,” International Journal of Pharmaceutics, vol. 380, no. 1-2, pp. 216–222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Shegokar and R. H. Müller, “Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives,” International Journal of Pharmaceutics, vol. 399, no. 1-2, pp. 129–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Petersen, “Nanocrystals for use in topical cosmetic formulations and method of production thereof,” US Patent Application No. 60/8866,233, 2006. View at Google Scholar
  7. H. Sucker and P. Gassmann, “Improvements in pharmaceutical compositions,” European Patent 0580690, 1992. View at Google Scholar
  8. M. List and H. Sucker, “Pharmaceutical colloidal hydrosols for injection,” GB Patent 2200048, 1988. View at Google Scholar
  9. H. Auweter, H. Bohn, R. Heger et al., “Precipitated water-insoluble colorants in colloid disperse form,” US Patent 6494924, 2002. View at Google Scholar
  10. H. Auweter, V. André, D. Horn, and E. Lüddecke, “The function of gelatin in controlled precipitation processes of nanosize particles,” Journal of Dispersion Science and Technology, vol. 19, no. 2-7, pp. 163–184, 1998. View at Google Scholar · View at Scopus
  11. B. C. Hancock and G. Zografi, “Characteristics and significance of the amorphous state in pharmaceutical systems,” Journal of Pharmaceutical Sciences, vol. 86, no. 1, pp. 1–12, 1997. View at Google Scholar · View at Scopus
  12. H. de Waard, W. L. J. Hinrichs, and H. W. Frijlink, “A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying,” Journal of Controlled Release, vol. 128, no. 2, pp. 179–183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. H. de Waard, N. Grasmeijer, W. L. J. Hinrichs, A. C. Eissens, P. P. F. Pfaffenbach, and H. W. Frijlink, “Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production,” European Journal of Pharmaceutical Sciences, vol. 38, no. 3, pp. 224–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G. G. Liversidge, K. C. Cundy, J. F. Bishop et al., “Surface modified drug nanoparticles,” US Patent 5145684, 1991. View at Google Scholar
  15. L. Peltonen and J. Hirvonen, “Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods,” Journal of Pharmacy and Pharmacology, vol. 62, no. 11, pp. 1569–1579, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Merisko-Liversidge, G. G. Liversidge, and E. R. Cooper, “Nanosizing: a formulation approach for poorly-water-soluble compounds,” European Journal of Pharmaceutical Sciences, vol. 18, no. 2, pp. 113–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Merisko-Liversidge and G. G. Liversidge, “Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology,” Advanced Drug Delivery Reviews, vol. 63, no. 6, pp. 427–440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. H. Müller, S. Gohla, and C. M. Keck, “State of the art of nanocrystals—special features, production, nanotoxicology aspects and intracellular delivery,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 78, no. 1, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Keck and R. H. Müller, “Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 62, no. 1, pp. 3–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. B. E. Rabinow, “Nanosuspensions in drug delivery,” Nature Reviews Drug Discovery, vol. 3, no. 9, pp. 785–796, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. R. H. Müller, K. Mäder, and K. Krause, “Verfahren zur schonenden Herstellung von hochfeinen Micro-/Nanopartikeln,” PCT Application PCT/EP00/06535, Germany, 2000. View at Google Scholar
  22. S. Khan and G. W. Pace, “Composition and method of preparing microparticles of water-insoluble substances,” US Patent 6337092, 2002. View at Google Scholar
  23. S. Majuru and M. O. Oyewumi, “Nanotechnology in drug development and life cycle management,” in Nanotechnology in Drug Delivery, M. M. Villiers, P. Aramwit, and G. S. Kwon, Eds., pp. 597–619, Springer, New York, NY, USA, 2009. View at Publisher · View at Google Scholar
  24. J. E. Kipp, J. C. T. Wong, M. J. Doty, and C. L. Rebbeck, “Microprecipitation method for preparing submicron suspensions,” US Patent 6869617, 2001. View at Google Scholar
  25. J. Kipp, J. Wong, M. Doty et al., “Microprecipitation method for preparing submicron nanosuspensions,” US Patent 6607784 B2, 2003. View at Google Scholar
  26. J. E. Kipp, J. C. T. Wong, M. J. Doty et al., “Method for preparing submicron particle suspensions,” US Patent 6884436, 2005. View at Google Scholar
  27. B. E. Rabinow, P. Gupta, J. Wong, P. Papadopoulos, and M. Chaubal, “Formulation of water-insoluble antineoplastic agents as nanosuspensions using NANOEDGE formulation technology,” in Proceedings of the American Association for Cancer Research (AACR '04), vol. 45, 2004, AACR Meeting Abstracts 1/146-a.
  28. J. E. Kipp, “The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs,” International Journal of Pharmaceutics, vol. 284, no. 1-2, pp. 109–122, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Rabinow, J. Kipp, P. Papadopoulos et al., “Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat,” International Journal of Pharmaceutics, vol. 339, no. 1-2, pp. 251–260, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Pu, J. Sun, Y. Wang et al., “Development of a chemically stable 10-hydroxycamptothecin nanosuspensions,” International Journal of Pharmaceutics, vol. 379, no. 1-2, pp. 167–173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Shelar, S. Pawar, and P. Vavia, “Fabrication of isradipine nanosuspension by anti-solvent microprecipitation-high-pressure homogenization method for enhancing dissolution rate and oral bioavailability,” Drug Delivery and Translational Research, no. 5, pp. 384–391, 2013. View at Publisher · View at Google Scholar
  32. A. J. Raval and M. M. Patel, “Preparation and characterization of nanoparticles for solubility and dissolution rate enhancement of meloxicam,” International Research Journal of Pharmaceuticals, vol. 1, no. 2, pp. 42–49, 2011. View at Google Scholar
  33. D. Xia, P. Quan, H. Piao et al., “Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability,” European Journal of Pharmaceutical Sciences, vol. 40, no. 4, pp. 325–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Zhang, Q. Xia, and N. Gu, “Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method,” Drug Development and Industrial Pharmacy, vol. 32, no. 7, pp. 857–863, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. H. S. M. Ali, P. York, A. M. A. Ali, and N. Blagden, “Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling,” Journal of Controlled Release, vol. 149, no. 2, pp. 175–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. H. S. M. Ali, P. York, and N. Blagden, “Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors,” International Journal of Pharmaceutics, vol. 375, no. 1-2, pp. 107–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. R. H. Müller and J. Möschwitzer, “Method and device for producing very fine particles and coating such particles,” US Patent 0297565 A1, 2009. View at Google Scholar
  38. B. Sinha, R. H. Müller, and J. Möschwitzer, “Precipitation followed by high presure homogenization as a combinative approach to prepare drug nanocrystals,” in Tag der Pharmazie, FU Berlin, Berlin, Germany, 2012, abstract V2, booklet page 6.
  39. J. Möschwitzer, “Method for producing ultrafine submicronic suspensions,” WO/002006094808A3, 2006. View at Google Scholar
  40. T. Liu, R. H. Müller, and J. P. Möschwitzer, “Process optimization of a novel particle size reduction technology H 42,” in Tag der Pharmazie, FU Berlin, Berlin, Germany, abstract P33, booklet page 25.
  41. J. Möschwitzer and A. Lemke, “Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof,” WO/2006/108637, 2006. View at Google Scholar
  42. J. Salazar, A. Ghanem, R. H. Müller, and J. P. Möschwitzer, “Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 81, no. 1, pp. 82–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. D. L. Teagarden and D. S. Baker, “Practical aspects of lyophilization using non-aqueous co-solvent systems,” European Journal of Pharmaceutical Sciences, vol. 15, no. 2, pp. 115–133, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Salazar, O. Heinzerling, R. H. Müller, and J. P. Möschwitzer, “Process optimization of a novel production method for nanosuspensions using design of experiments (DoE),” International Journal of Pharmaceutics, vol. 420, no. 2, pp. 395–403, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Staedtke, M. Brähler, A. Müller et al., “In vitro inhibition of fungal activity by macrophagemediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells,” Small, vol. 6, no. 1, pp. 96–103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Möschwitzer, “Drug nanocrystals in the commercial pharmaceutical development process,” International Journal of Pharmaceutics, vol. 453, no. 1, pp. 142–156, 2013. View at Publisher · View at Google Scholar
  47. C. M. Keck, S. Kobierski Mauludin R, and R. H. Müller, “Second generation of drug nanocrystals for delivery of poorly soluble drugs: smartCrystal technology,” Dosis, vol. 24, no. 2, pp. 124–128, 2008. View at Google Scholar
  48. S. Kobierski and C. M. Keck, “Characterization of hydroxyethyl starches with different molecular weights by asymmetrical flow field-flow fractionation,” in Proceedings of the Annual Meeting of the Controlled Release Society Local Chapter, vol. 40, Braunschweig, Germany, March 2008.
  49. L. Al Shaal, R. H. Müller, and R. Shegokar, “SmartCrystal combination technology—scale up from lab to pilot scale and long term stability,” Pharmazie, vol. 65, no. 12, pp. 877–884, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. M. V. Chaubal, “Application of formulation technologies in lead candidate selection and optimization,” Drug Discovery Today, vol. 9, no. 14, pp. 603–609, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Salazar, J. Möschwitzer, and R. H. Müller, “Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets,” European Journal of Pharmaceutical Sciences, vol. 49, no. 4, pp. 565–577, 2012. View at Publisher · View at Google Scholar